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Tumor stroma is required for the survival, 
growth, and progression of cancers. The major 
components in tumor stroma are fi  broblasts, 
neovasculature, and tumor-associated  macro-
phages. Stroma inhibits infi  ltration and ac-
tivation of tumor T cells (1–4). However, it 
is poorly understood how each cellular com-
ponent in tumor stroma contributes to tumor 
immunopathogenesis (5). Mouse tumor mac-
rophages are proposed to subvert tumor-spe-
cifi  c immunity. However, the suppressive roles 
and mechanisms are not well understood in the 
immunopathogenesis of human cancers.
APCs are critical for initiating and maintain-
ing tumor-associated antigen (TAA)-specifi  c 
T cell immunity. Tumor macrophages markedly 
outnumber other APCs, such as DCs, and 
represent an abundant population of APCs in 
solid tumors (6–9). Strikingly, numerous studies 
have investigated the phenotypes and functions 
of DCs in tumor immunity (5, 10–18). Studies 
in mice have also revealed that tumor macro-
phages promote tumor growth and metastasis by 
directly acting on tumor cells (6–9). Immuno-
histochemical assessment of the number and 
the distribution of tumor macrophages in hu-
man tumors has yielded scant, and often con-
tradictory, results regarding any potential role 
in tumor pathogenesis (19–21). Thus, immune 
functional data are essential for understanding 
the roles and potential suppressive mechanisms 
of human tumor environmental macrophages 
in tumor immunopathogenesis.
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Tumor-associated macrophages are a prominent component of ovarian cancer stroma and 
contribute to tumor progression. B7-H4 is a recently identifi  ed B7 family molecule. We 
show that primary ovarian tumor cells express intracellular B7-H4, whereas a fraction of 
tumor macrophages expresses surface B7-H4. B7-H4+ tumor macrophages, but not primary 
ovarian tumor cells, suppress tumor-associated antigen-specifi  c T cell immunity. Blocking 
B7-H4-, but not arginase-, inducible nitric oxide synthase or B7-H1 restored the T cell 
stimulating capacity of the macrophages and contributes to tumor regression in vivo. 
Interleukin (IL)-6 and IL-10 are found in high concentrations in the tumor microenviron-
ment. These cytokines stimulate macrophage B7-H4 expression. In contrast, granulocyte/
macrophage colony-stimulating factor and IL-4, which are limited in the tumor microenvi-
ronment, inhibit B7-H4 expression. Ectopic expression of B7-H4 makes normal macro-
phages suppressive. Thus, B7-H4+ tumor macrophages constitute a novel suppressor cell 
population in ovarian cancer. B7-H4 expression represents a critical checkpoint in deter-
mining host responses to dysfunctional cytokines in ovarian cancer. Blocking B7-H4 or 
depleting B7-H4+ tumor macrophages may represent novel strategies to enhance T cell 
tumor immunity in cancer.
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B7-H4 (B7x, B7S1), a recently discovered member of the 
B7 family of T cell costimulatory molecules, is a negative 
regulator of T cell responses in vitro by inhibiting T cell pro-
liferation, cell cycle progression, and cytokine production 
(22–25). Antigen-specifi  c T cell responses are impaired in 
mice treated with a B7-H4Ig fusion protein (22). However, 
the expression, regulation, and function of B7-H4 are virtu-
ally unknown in the context of human immunity.
We recently described several mechanisms in the human 
ovarian cancer microenvironment that actively defeat tumor 
immunity (5, 26, 27), including an immunopathologic role 
for regulatory T cells (26–28). As tumor macrophages are far 
more abundant than regulatory T cells in the highly dysfunc-
tional ovarian cancer microenvironment, we investigated the 
possibility that B7-H4+ tumor macrophages are a novel reg-
ulatory cell population in ovarian cancer, and also investi-
gated a role for B7-H4 signals in this regard.
RESULTS
Ovarian tumors express intracellular B7-H4
Based on the phenotype of lin−EpCam+CD45−CD14−, we 
initially isolated and sorted primary fresh ovarian tumor cells 
from ovarian cancer ascites fl  uid and from the tumor mass. 
We observed that fresh ovarian tumors expressed B7-H4 
mRNA, and exclusively expressed intracellular rather than 
cell surface B7-H4 protein (Fig. 1 a). In support of this, our 
established ovarian tumor cell lines expressed B7-H4 mRNA 
(Fig. 1 b), but <5% expressed surface B7-H4 and >85% 
  expressed intracellular B7-H4 (Fig. 1 b).
Ovarian tumor-associated macrophages express surface B7-H4
We then studied ovarian tumor macrophages. >70% of 
freshly isolated tumor macrophages expressed cell surface 
B7-H4 protein (Fig. 2). Freshly isolated tumor ascites CD14+ 
tumor macrophages from previously untreated patients with 
ovarian cancer (n = 12) expressed signifi  cantly more B7-H4 
compared with macrophages from nonmalignant ascites (liver 
transplant patients, n = 5) or normal peripheral blood mono-
cytes (n = 25; P = 0.02 for both) (Fig. 2, a and b). The prev-
alence of B7-H4+ tumor macrophages was markedly higher 
than that of CD4+CD25+CD3+ regulatory T cells (T reg 
cells) (n = 12; *, P < 0.001) in tumor ascites (Fig. 2 c). Using 
confocal microscopy, we confi   rmed that 70% ± 12% of 
Ham56+ tumor macrophages (n = 60) (Fig. 2 d) and 100% 
ovarian epithelial carcinoma cells strongly expressed B7-H4 
(Fig. 2 e), whereas tumor-infi  ltrating CD3+ T cells (Fig. 2 e) 
and tumor ascites CD3+ T cells did not (unpublished data). 
Similar levels of B7-H4 expression were observed on CD68+ 
tumor macrophages. Interestingly, tumor islets were gener-
ally surrounded by B7-H4+ tumor macrophages (Fig. 2, d 
and e). Together, these data indicate selective cell surface ex-
pression of B7-H4 on tumor macrophages.
Phenotypes of B7-H4+ tumor macrophages
To study the nature of B7-H4+ tumor macrophages, we com-
pared the phenotypes of B7-H4+ tumor macrophages with 
B7-H4− tumor macrophages. Most of the T cell activation-
related molecules (HLA-DR, HLA-ABC, CD40, CD54, and 
CD80) were expressed at similar levels on B7-H4+ tumor mac-
rophages and B7-H4− tumor macrophages (Table S1, avail  able 
at http://www.jem.org/cgi/content/full/jem.20050930/DC1). 
However, B7-H4+ tumor macrophages expressed higher 
levels of CD86 than B7-H4− tumor macrophages (P = 0.04) 
(Table S1). Furthermore, after LPS stimulation both B7-H4+ 
tumor macrophages and B7-H4− tumor macrophages pro-
duced comparable levels of several cytokines including IL-6, 
IL-10, and TNF-α (unpublished data).
Tumor microenvironmental factors induce macrophage 
B7-H4 expression
Because tumor macrophages, but not normal macrophages 
or monocytes expressed high level B7-H4, we hypothe-
sized that tumor microenvironmental factors may stimulate 
B7-H4 expression on tumor macrophages. To test this, we 
incubated normal blood monocytes with serum-free me-
dium or tumor ascites. Tumor ascites induced signifi  cant 
B7-H4 expression (n = 12; P < 0.0001) (Fig. 3 a). Addi-
tion of a neutralizing monoclonal antibody against IL-6 
signifi  cantly blocked tumor ascites-mediated B7-H4 up-
regulation (n = 5; P < 0.001) (Fig. 3 a), and neutralizing 
Figure 1.  Ovarian tumor cells express intracellular B7-H4. B7-H4 
expression was analyzed by RT-PCR and FACS in (a) fresh primary ovarian 
tumor cells and (b) ovarian tumor cell lines. FACS results expressed the 
mean percentage of B7-H4–expressing cells. OC8, OC21, and OC38 are 
three established ovarian tumor cell lines. Fresh primary ovarian tumor cells 
were isolated and sorted from ascites and tumor tissues with a phenotype 
of lin−EpCam+CD45−CD14−. Two of six representative patient samples 
are shown for panel a. Three of eight cell lines are shown for panel b. Filled 
histogram, B7-H4 expression; open histogram, isotype control.JEM VOL. 203, April 17, 2006  873
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monoclonal antibody against IL-10 partially reduced tumor 
ascites-mediated B7-H4 up-regulation (n = 5; P = 0.053) 
(Fig. 3 a). Simultaneous blockade of IL-6 and IL-10 com-
pletely abrogated tumor ascites-induced B7-H4 (Fig. 3 a), 
suggesting that IL-6 and IL-10 in tumor ascites cooperate
to stimulate macrophage B7-H4 expression. In support, we 
detected high levels of IL-6 and IL-10 mRNA in ovarian
tumor tissues (unpublished data) and protein in tumor ascites 
fl  uid (n = 11) (Fig. 3 b). We further incubated ovarian 
tumor cells with tumor ascites. Tumor   ascites had no   eff  ect 
on intracellular or cell surface B7-H4   expression in tumor 
cells (Fig. S1 A, http://www.jem.org/cgi/content/full/
jem.20050930/DC1).
Tumor environmental IL-6 and IL-10 induce macrophage 
B7-H4 expression
In further support of these data, recombinant IL-6 and IL-10 
stimulated signifi  cant B7-H4 protein expression on normal 
blood monocytes in a dose-dependent manner (n = 12; P < 
0.05 for all) (Fig. 3 c). In further support, recombinant IL-10 
induced a dose-dependent induction of B7-H4 mRNA ex-
pression (Fig. 3 d). High levels of vascular endothelial growth 
factor (VEGF) and stromal-derived factor (SDF)-1 were 
found in ovarian tumor environments (11, 29). We observed 
that VEGF and SDF-1 had no eff  ects on monocyte B7-H4 
expression (unpublished data). Interestingly, IL-4 and GM-
CSF blocked the IL-10–induced B7-H4 expression of 
mRNA (Fig. 3 d) and protein (Fig. 3 e) (n = 7; P < 0.05 for 
all, compared with medium). Finally, negligible levels of IL-4 
and GM-CSF were detected in tumor ascites (<10 ng/ml for 
each) and tumor tissues (unpublished data). These data indi-
cate that an imbalanced tumor environmental cytokine pat-
tern (high IL-10 and IL-6, low IL-4 and GM-CSF) may 
condition local macrophages to become dysfunctional, and 
that stimulation of B7-H4 might be a potential mechanism. 
As expected, recombinant IL-6, IL-10, IL-4, and GM-CSF 
had no eff  ect on B7-H4 mRNA and protein expression in 
tumor cells (Fig. S1, b and c). The data suggest a distinct reg-
ulatory mechanism for B7-H4 expression on tumor cells 
compared with APCs.
Figure 2.  Tumor-associated macrophages express B7-H4. 
(a and b) Tumor ascites macrophages express B7-H4. FACS analysis showed 
that ascites macrophages, but not control nonmalignant ascites macrophages, 
or fresh normal blood monocytes expressed B7-H4. Results are expressed 
as the mean of the percentage of B7-H4+ cells ± SEM in total macro-
phages. Filled histogram, B7-H4 staining; open histogram, isotype control. 
(c) High prevalence of B7-H4+ tumor macrophages in tumor ascites. FACS 
analysis was used to determine the prevalence of B7-H4+ tumor macro-
phages and CD3+CD4+CD25+ cells in tumor ascites (*, P < 0.001). Results 
are expressed as the mean of percentage ± SEM in tumor ascites 
  mononuclear cells. (d and e) Tumor tissues were stained with anti–human 
B7-H4, anti–human CD3, anti–human-Ham56, and control antibody as 
described in Materials and methods, and analyzed with confocal micro-
scope. (d) Tumor mass macrophages and tumor cells express B7-H4. 
B7-H4, green; Ham56, red. Tumor macrophages are identifi  ed as Ham56+ 
cells (red). Ham56+B7-H4+ cells are yellowish. Large numbers of tumor 
macrophages form a barrier surrounding tumor islets. (e) Tumor-
 infi  ltrating T cells are B7-H4−. Tumor cells, but not CD3+ T cells (red), 
expressed B7-H4 (green). 1 of 60 representative patient samples 
is shown for panels d and e.874  MACROPHAGE B7-H4 AND TUMOR IMMUNITY | Kryczek et al.
B7-H4+ tumor macrophages suppress Her-2/neu-specifi  c 
T cell immunity
To determine the immunopathological signifi  cance of tumor 
macrophages, we used our in vitro TAA-specifi  c culture system 
(10, 11). Myeloid dendritic cells (MDCs) were diff  erentiated 
from HLA-A2+ monocytes as we described previously (30), 
and loaded with HLA-A2-specifi  c, Her-2/neu peptides (TAA-
MDC) (26, 31). Addition of autologous TAA-MDC induced 
specifi  c T cell activation as expected (Fig. 4). Autologous tumor 
macrophages isolated from tumor tissues of HLA A2+ patients 
with Her-2/neu+ tumors signifi   cantly inhibited MDC-
  mediated, Her2/neu-specifi  c T cell proliferation in a dose-
  dependent manner (n = 5; P < 0.05) (Fig. 4 a). IFN-γ (Fig. 4, 
b and c) and IL-2 (Fig. 4, b and d) production (n = 5; *, P < 
0.01) and Her-2/neu–specifi  c cytotoxicity (n = 5; P < 0.05) 
(Fig. 4 e) were also inhibited by addition of autologous tumor 
macrophages. Tumor macrophages isolated from tumor ascites 
showed similar suppressive eff  ects. MDCs alone did not induce 
T cell activation (<2,000 counts per minute [cpm]). Limited 
T cell proliferation was observed in the absence of TAA-MDC 
stimulation (<1,000 cpm). Further, when tumor macrophages 
were replaced with irradiated autologous ovarian tumor cells in 
the identical experimental setting, irradiated autologous tumor 
cells had no eff  ects on T cell activation (unpublished data).
We then sorted B7-H4+ and B7-H4− tumor macro-
phages to defi  ne their functional characteristics. Normal pe-
ripheral blood monocytes were cultured for 48 h with M-CSF 
to generate normal macrophages (26). Normal macrophages 
induced dose-dependent T cell proliferation (Fig. 4 f). How-
ever, both B7-H4+ and B7-H4− tumor macrophages signi-
fi  cantly suppressed T cell proliferation in a dose-dependent 
manner (n = 5; P < 0.01 for all, compared with normal mac-
rophages and no macrophages) (Fig. 4 f). Furthermore, B7-
H4+ tumor macrophages were two- to sixfold more potent 
than B7-H4− tumor macrophages in mediating T cell sup-
pression (n = 5; P < 0.01 for all, compared with normal 
macrophages and no macrophages) (Fig. 4 f). Further, >70% 
tumor macrophages express B7-H4 (Fig. 2). These data 
  suggest that total tumor macrophage-mediated immuno-
suppression comes predominantly from the B7-H4+ tumor 
macrophage subset.
Role of B7-H4 on macrophages mediates 
immunosuppression in vitro
We then focused on B7-H4+ tumor macrophages to deter-
mine their role in T cell suppression. As blocking B7-H4 
  antibody is not available, we designed B7-H4–specifi  c mor-
pholino antisense oligonucleotides (B7-H4 blocking oligos) 
Figure 3.  Tumor ascites IL-6 and IL-10 stimulate macrophage 
B7-H4 expression. (a) Tumor ascites stimulated macrophage B7-H4 
expression. Fresh normal blood monocytes were cultured 72 h with ovarian 
tumor ascites in the presence or absence of anti–human IL-6 or anti–
human IL-10 antibodies. B7-H4 expression was analyzed by FACS. Results 
are expressed as the mean of B7-H4+ cell percentage ± SEM in total 
macrophages. (b) High concentrations of IL-6 and IL-10 in tumor ascites 
were detected by ELISA. (c) Recombinant IL-6 or IL-10 stimulated macro-
phage B7-H4 protein in a dose-dependent manner after a 72 h culture. 
B7-H4 expression was analyzed by FACS. Results are expressed as the 
mean of B7-H4+ cell percentage ± SEM in total macrophages. 
(d and e) Recombinant IL-4 and GM-CSF reduced macrophage B7-H4 
mRNA and protein induction. Fresh blood monocytes were cultured with 
different concentrations of cytokines. (d) B7-H4 mRNA was detected by 
RT-PCR at 24 h. (e) B7-H4 surface protein was detected by FACS at 72 h. 
One of seven independent experiments is shown.JEM VOL. 203, April 17, 2006  875
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and an inverted control oligonucleotide (control oligos). We 
initially studied the eff  ect of medium, IL-10, and tumor ascites-
conditioned macrophages. The B7-H4–blocking oligos, but 
not control oligos, signifi  cantly inhibited basal, IL-10, and 
tumor ascites-induced B7-H4 mRNA expression by over 
1,000-fold (Fig. 5 a) and B7-H4 protein expression by over 
3-fold (n = 6; P < 0.05) (Fig. 5 b). Neither B7-H4–blocking 
oligos nor control oligos aff  ected macrophage CD14, CD40, 
CD80, CD86, B7-H1, HLA-ABC, HLA-DR, or IL-6 and 
TNF-α expression (unpublished data). These data indicate 
that our B7-H4–blocking oligos selectively block B7-H4 
  expression in macrophages.
We further tested whether B7-H4–blocking oligos 
  aff  ected tumor ascites-conditioned macrophage function. 
T cell proliferation was signifi  cantly increased when stimu-
lated with tumor ascites-conditioned macrophages initially 
exposed to B7-H4–blocking oligos compared with con-
trol oligos (n = 4; P < 0.001) (Fig. 5 c). This coincided 
with a signifi  cant decrease in B7-H4 expression (Fig. 5, 
a and b). Further, B7-H4–blocking oligos promoted T cell 
exit from G0/G1 phase and entry into S phase (n = 3; 
P < 0.05) (Fig. 5 d). Together, these data indicate that 
B7-H4 contributes to tumor macrophage-mediated  immuno-
suppression in vitro.
B7-H4+ macrophages mediate an immunosuppression 
independent of B7-H1, arginase and inducible nitric oxide 
synthase (iNOS)
B7-H1, arginase, and iNOS were reported to be implicated 
in dendritic cells, mouse macrophage, and myeloid suppres-
sor cell–mediated T cell suppression (32–41). To study the 
additional suppressive mechanism of tumor macrophages, we 
fi  rst analyzed the expression of B7-H1, arginase, and iNOS 
in B7-H4+ macrophages from ovarian cancer ascites. Flow 
cytometry analysis demonstrated that the levels of B7-H1 
  expression were signifi  cantly low (20% in average, P < 0.05) 
and variable (from 2 to 51%) on B7-H4+ macrophages (Fig. 
6 a). Western blot analysis revealed limited arginase expres-
sion and variable iNOS expression in macrophages among 
patients (Fig. 6 a). We further tested the role of B7-H1, 
  arginase, and iNOS in T cell activation. We observed that 
  blocking B7-H1 with specifi  c B7-H1–neutralizing antibody 
(anti–B7-H1) (10, 42, 43), the addition of selective inhibitors 
of iNOS (L-NMMA) and of arginase (nor-LOHA) (32–41) 
slightly (<13%), but not signifi  cantly, reduced macrophage-
mediated T cell suppression compared with treatment with 
isotype-matched control antibody and control oligos (Fig. 6 b). 
As expected, blocking B7-H4 with B7-H4–specifi  c oligos 
signifi  cantly reduced the suppression (n = 5; *, P < 0.05) 
(Fig. 6 b). The data indicate that B7-H4, but not B7-H1, 
  arginase, and iNOS, play a predominant role in B7-H4+ 
macrophage-mediated suppression.
Ectopic B7-H4 expression confers macrophage 
suppressive capacity
We tested whether B7-H4 expression was suffi   cient  to 
  confer a suppressive phenotype on B7-H4–negative normal 
cells by transducing normal blood monocytes with human 
B7-H4 cDNA. 20 h after transfection, 50–70% cells ex-
pressed B7-H4 or GFP (positive control), whereas <5% 
B7-H4 expression was observed on cells without transfec-
tion (negative control) (Fig. 7 a). We observed similar trans-
fection effi     ciency with B7-H1 transfection (unpublished 
data). B7-H4–transfected cells were subject to coculture 
with T cells. As expected, B7-H4–transfected cells, but not 
control-transfected cells or nontransfected cells, suppressed 
T cell proliferation in a dose-dependent manner (n = 4; 
P < 0.05 for all, compared with controls) (Fig. 7 b). These 
data indicate that ectopic B7-H4 expression confers macro-
phage suppressive capacity.
Figure 4.  Tumor macrophages suppress TAA-specifi  c T cell immu-
nity in vitro. (a–e) Autologous tumor ascites CD3+CD25− T cells were 
stimulated with Her-2/neu peptide-loaded MDC (TAA-MDC) as described 
in Materials and methods. (a) Tumor T cell proliferation was detected by 
[3H]thymidine incorporation (CPM). Results are expressed as the mean of 
cpm ± SEM. TAA-specifi  c T cell IFN-γ (b and c) and IL-2 (b and d) produc-
tion was detected by intracellular staining (FACS) and ELISA. (e) Tumor 
macrophages inhibited Her-2/neu–specifi  c T cell cytotoxicity. MDC-acti-
vated Her-2/neu–specifi  c T cells were effector cells, and Her-2/neu peptide-
loaded T2 cells were target cells. Her-2/neu–specifi  c cytotoxicity was 
determined by FACS (see Materials and methods). Tumor macrophage to 
TAA-MDC ratio was 1:1 for panels b–e. (f) B7-H4+ tumor macrophages 
signifi  cantly suppress T cell proliferation. B7-H4+ or B7-H4− tumor macro-
phages were sorted from malignant ascites using a FACSaria. Normal 
macrophages were from M-CSF–treated normal peripheral blood mono-
cytes. Tumor ascites CD3+ T cells were stimulated with anti-CD3 antibody 
and blood monocytes for 3 d in the presence of different concentrations 
of tumor macrophages or normal macrophages. T cell proliferation was 
detected by [3H]thymidine incorporation. Results are expressed as the 
mean of cpm ± SEM. TAM, tumor macrophages; macrophage, MΦ.876  MACROPHAGE B7-H4 AND TUMOR IMMUNITY | Kryczek et al.
Blocking B7-H4 on macrophages improves TAA-specifi  c 
T cell immunity in vivo
To test the eff  ect of macrophage B7-H4 on TAA-specifi  c 
T cell immunity in vivo, we treated tumor ascites-conditioned 
macrophages with B7-H4–blocking oligos or control oligos 
and then injected them plus autologous TAA-specifi  c T cells 
into our established human NOD/SCID mice bearing the 
corresponding ovarian tumors (26). As expected, mice with-
out T cell transfusion, and mice treated with TAA-specifi  c 
T cells plus control oligo-treated macrophages, showed pro-
gressive tumor growth. Supporting our hypothesis that tumor 
macrophage B7-H4 signals are immunopathologic in vivo, 
mice treated with TAA-specifi  c T cells plus B7-H4–blocking 
oligo-treated macrophages showed reduced tumor volumes 
at each time point from day 7 (n = 5–7 mice per group;
*, P < 0.05, compared with B7-H4–blocking oligo) (Fig. 8 a). 
These data indicate that tumor macrophages defeat TAA-
  specifi  c T cell immunity in vivo through B7-H4 signals and 
contribute to tumor growth. Further, confocal microscopic 
analysis showed that macrophages and T cells were localized 
in the tumors and the engagement between macrophages and 
T cells were found in the tumor (Fig. 8 b).
DISCUSSION
After several decades of neglect, immune suppressor cells 
are once again an area of active research interest. The best 
studied immune suppressor population is the well-known 
yet still relatively newly described CD4+CD25+ T reg cells 
(44–46). Human T reg cells (26, 47) disable TAA-specifi  c 
T cell immunity (5, 27). We now report a novel suppressive 
cell population in patients with ovarian carcinoma, namely 
B7-H4+ macrophages.
Based on studies in murine systems, macrophages are func-
tionally classifi  ed into M1 and M2 (48). Functionally, M1s 
may produce IL-12, TNF-α, and nitric oxide and induce 
T helper 1 responses, whereas M2s may produce arginase, 
but not IL-12, and play an important role in tissue repair and 
development. Analogously, in the context of tumor  immunity, 
M1s were suggested to induce protective tumor immunity 
and result in tumor regression, whereas M2s were suggested 
to promote tumor growth and tumor angiogenesis (6, 7, 32, 
34, 48). For example, studies in murine tumor models dem-
onstrate that myeloid suppressor cells, including immature 
macrophages, suppress T cell activation by various mecha-
nisms including releasing NO and arginase (32–41, 49). In-
terestingly, a recent study demonstrated that human prostate 
cancer cells apply similar mechanisms to induce T cell un-
responsiveness (39, 40). Strikingly, immunohistochemical 
  assessment of the number and the distribution of tumor
macrophages in human tumors has yielded scant and often 
contradictory results regarding any potential role in tumor 
immunopathogenesis (19–21). To address the functional rel-
evance of human tumor macrophages, we sorted human 
ovarian tumor–associated macrophages to conduct in vitro 
and in vivo immune functional experiments. We now docu-
ment that a fraction of tumor macrophages that expresses 
Figure 5.  Blockade of B7-H4 improved macrophage-mediated 
T cell activation. (a and b) B7-H4–blocking oligos reduced macrophage 
B7-H4 expression. Fresh blood monocytes were exposed to B7-H4–
  blocking oligos and control oligos with medium, tumor ascites, and IL-10. 
(a) B7-H4 mRNA was detected at 24 h by RT-PCR with serial dilutions 
of cDNA. (b) B7-H4 protein was detected at 72 h by FACS. One of nine 
independent experiments is shown. (c and d) Blockade of B7-H4 improved 
tumor ascites-conditioned macrophage-mediated T cell activation in vitro. 
Tumor ascites-conditioned macrophages were previously treated with 
B7-H4–blocking oligos or control oligos and were subsequently 
subject to activating T cells for 72 h. (c) T cell proliferation was measured 
by [3H]thymidine incorporation. Results are expressed as the mean of 
cpm ± SEM. (d) Cell cycle in T cells was analyzed by FACS. Results are ex-
pressed as the mean of the percentage of T cells ± SEM in each cycle phase. 
The ratio between macrophages and T cells was 1:1 for panel d. n = 4–8; 
*, P < 0.05 compared with control oligos.JEM VOL. 203, April 17, 2006  877
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B7-H4 signifi  cantly inhibits TAA-specifi  c T cell prolifera-
tion, cytokine production, and cytotoxicity in vitro. These 
B7-H4+ tumor macrophages also inhibit TAA-specifi  c im-
munity in vivo and foster tumor growth in chimeric SCID/
NOD mice bearing autologous human tumors, despite the 
presence of potent TAA-specifi  c eff  ector T cells. The notion 
that tumor macrophage B7-H4 signals contribute to immuno-
pathology is supported by several lines of evidence. First,
B7-H4+ tumor macrophages are signifi  cantly more suppres-
sive than B7-H4− tumor macrophages. Second, blocking 
B7-H4 on tumor-conditioned macrophages disables their 
suppressive capacity. Third, forced B7-H4 expression renders 
normal macrophages suppressive. Fourth, blocking B7-H1 
and inhibiting iNOS and arginase have minor eff  ects on 
B7-H4+ macrophage-mediated T cell suppression. It remains 
to be defi   ned whether ovarian tumor–associated myeloid 
suppressor cells and ovarian tumor cells would release iNOS 
and arginase and, in turn, result in T cell suppression.
These fi  ndings establish B7-H4+ tumor macrophages as 
a novel immune regulatory population in human ovarian 
  cancer. Our data here indicate that the suppressive potency of 
B7-H4+ macrophages is similar to that of CD4+ T reg cells 
(26). Interestingly, B7-H4+ tumor macrophages and CD4+ 
T reg cells, the two functionally suppressive immune cell 
populations, are not only physically localized in ovarian 
  tumor environment (26), but our recent observations also 
suggest a mechanistic link between B7-H4+ APCs (including 
macrophages) and CD4+ T reg cells (27, 28). In fact, CD4+ 
T reg cells stimulate APC B7-H4 expression and enable APC 
suppressive activity through B7-H4 induction (28). B7-H4+ 
tumor macrophages signifi   cantly outnumber CD4+ T reg 
cells in ascites and the solid tumor mass. Thus, their contribu-
tion to tumor immune evasion is likely substantial. Our fi  nd-
ings clearly establish the presence of a novel suppressor cell 
population in human cancer that forces a reexamination of 
the relative importance of T reg cells in the immunopatho-
genesis of cancer, and a rethinking of strategies to improve 
TAA-specifi   c immunity through abrogation of suppressor 
cell function (2, 13–17, 50–53).
B7-H4 is a newly identifi  ed B7 family member (22–24). 
Although mouse B7-H4 ligation of T cells has an inhibitory 
eff  ect on T cell activation (22, 23), the regulatory mecha-
nisms and the function of human B7-H4 remain to be de-
fi  ned in human immunology. We show for the fi  rst time that 
recombinant and tumor environmental IL-6 and IL-10 
  stimulate monocyte/macrophage B7-H4 expression, and that 
GM-CSF and IL-4 reduce B7-H4 expression. We also 
Figure 6.  B7-H4+ macrophages mediate an immunosuppression 
independent of B7-H1, arginase, and iNOS. (a) B7-H1, arginase, and 
iNOS expression on tumor ascites-associated macrophages. B7-H1 expres-
sion was analyzed by FACS. Arginase I and iNOS expression was detected 
by Western blot. A, B, C, D, and E represent 5 individual patients with 
ovarian cancer. (b) Tumor ascites-conditioned macrophages mediated 
T cell suppression through B7-H4. T cells were stimulated with tumor 
ascites-conditioned macrophages for 72 h in the presence of the indicated 
conditions. T cell proliferation was measured by [3H]thymidine incorporation 
in the last 16 h. The results were expressed as the percentage of suppres-
sion (mean ± SEM). The ratio between macrophages and T cells was 1:2 for 
panel d. n = 5; *, P < 0.05.
Figure 7.  Forced B7-H4 expression confers suppressive capacity of 
normal macrophages. Fresh blood monocytes were transfected using a 
plasmid encoding human B7-H4 or EGFP cDNA or control plasmid carried 
the reversed cDNA sequence of B7-H4. (a) 20 h after transfection, B7-H4 
and GFP expression were detected by FACS. One of fi  ve experiments is 
shown. (b) Different concentrations of the transfected cells were added 
into T cell culture in the presence of anti–human CD3 and normal mono-
cytes. T cell proliferation was detected by [3H]thymidine incorporation on 
day 3. One of fi  ve experiments is shown.878  MACROPHAGE B7-H4 AND TUMOR IMMUNITY | Kryczek et al.
  observed similar regulatory mechanism for B7-H4 expression 
on myeloid dendritic cells (28). Tumor cells, tumor-associ-
ated macrophages, and T reg cells may be the source for IL-6 
and IL-10 (11, 26). These data provide mechanisms for how 
tumor environmental IL-6 and IL-10 induce immune dys-
function. GM-CSF has been used to boost TAA-specifi  c 
  immunity in mouse cancer models (54, 55). A proposed 
mechanism for GM-CSF effi   cacy in these models is diff  eren-
tiation or attraction of DCs that boost TAA-specifi  c immu-
nity. In light of our present work, it will be interesting and 
worthwhile to reexamine these GM-CSF studies to deter-
mine whether a GM-CSF–mediated reduction in APC 
B7-H4 expression accounts for effi   cacy.
Additionally, we show for the fi  rst time that   dysfunctional 
tumor microenvironmental cytokine balances   signifi  cantly 
inhibit TAA-specifi  c immunity by stimulating macrophage 
B7-H4 expression. This conclusion is supported by the fol-
lowing evidence. First, tumor macrophages, but not normal 
macrophages, strongly express B7-H4 that inhibits TAA-
  specifi  c immunity. Second, we found high concentrations of 
IL-6 and IL-10, but not GM-CSF and IL-4, in the tumor 
microenvironment. IL-6 and IL-10 strongly stimulate mac-
rophage B7-H4 expression, whereas IL-4 and GM-CSF 
strongly suppress it. Third, GM-CSF and IL-4 reduce   tumor 
microenvironmental cytokine-induced macrophage B7-H4 
expression. Fourth, tumor-conditioned macrophages impair 
TAA-specifi  c T cell immunity through B7-H4 signals. Our 
data and those of others collectively demonstrate a new im-
mune evasion strategy whereby tumors maximize local toler-
izing conditions through suppressing DC diff  erentiation 
while simultaneously inducing macrophage B7-H4 expres-
sion. These ends are mediated through maximal local accu-
mulation of B7-H4–inducing cytokines, IL-6 and IL-10, 
in the virtual absence of B7-H4–reducing and DC diff  eren-
tiation cytokines, GM-CSF and IL-4. Strikingly, although 
ovarian tumor cells express B7-H4, it appears that tumor 
B7-H4 expression is exclusively intracellular and unable to 
induce T cell suppression in our in vitro culture system. 
Further, cytokines IL-4, GM-CSF, IL-6, and IL-10 have no 
regulatory eff  ects on tumor B7-H4 expression. Although 
the potential in vivo pathological relevance of tumor 
B7-H4 remains to be defi  ned, our data suggest that tumor 
B7-H4 and APC B7-H4 may be functionally distinct and 
diff  erentially regulated.
In summary, our study defi  nes the B7-H4+ macrophage 
as a novel suppressive cell population, and the inhibitory 
molecule B7-H4 is essential for their suppressive activity. 
The ovarian cancer microenvironment presents an over-
whelming arsenal of actively tolerizing mechanisms, includ-
ing an imbalance of plasmacytoid versus myeloid DCs (11), 
costimulatory molecules versus coinhibitory molecules (this 
work) (10, 25), and regulatory versus eff  ector T cells (26). 
Although of important concern for the prospects to use ef-
fective immune-based therapy against ovarian cancer, these 
mechanisms provide many new avenues for development of 
novel immune-based therapies.
MATERIALS AND METHODS
Human subjects. We studied previously untreated patients with epithelial 
ovarian carcinomas (International Federation of Gynecology and Obstetrics 
stage III or IV). Patients gave written, informed consent. The study was 
  approved by the Tulane Institutional Review Board.
Cells and tissue biopsies. Cells were obtained from ascites, fresh ovar-
ian tumor tissues, and peripheral blood as described (11). CD3+ T cells 
and CD14+ cells were purifi   ed with paramagnetic beads (StemCell 
  Technology) and sorted with FACSaria using DiVa software (Becton 
Dickinson Immunocytometry Systems). B7-H4+ and B7-H4− ascites 
macrophages, lin−EpCam+CD45−CD14− epithelial ovarian tumor cells 
were sorted on a FACSaria using DiVa software (Becton Dickinson). Cell 
populations were >98% pure as confi  rmed by fl  ow cytometry (FACSCal-
ibur; Becton Dickinson).
Phenotypes of tumor cells and macrophages. The phenotypes of 
  tumor cells and tumor ascites-conditioned macrophages were determined 
by RT-PCR or FACS. B7-H4 mRNA was detected by RT-PCR with 
specifi  c primers: 5′-G  T  C  G  G  A  G  C  A  G  G  A  T  G  A  A  A  T  G  T  -3′ (sense) and 5′-
C  A  G  G  A  G  T  A  T  G  T  G  T  T  G  T  T  G  A  T  -3′ (antisense). The surface expression 
of B7-H4, CD40, CD54, CD80, CD86, B7-H1, HLA-ABC, and HLA-DR 
Figure 8.  Blockade of B7-H4 improved macrophage-mediated 
T cell activation in vivo. (a) Blocking tumor ascites-conditioned macro-
phage B7-H4 results in tumor regression in vivo. Mice were injected with 
human primary ovarian tumors as described in Materials and methods. 
Controls received no additional injection (▲, group 1). Treatments were 
tumor-specifi  c T cells plus B7-H4–blocking oligo-treated macrophages 
(○, group 2), and tumor-specifi  c T cells plus control oligo-treated macro-
phages (■, group 3). Mean ± SD of tumor volumes is shown (n = 5–7 
mice per group). The T cell injection day was counted as day 0. Macro-
phage, MΦ. (b) Macrophages and T cell were colocalized in tumor tissue. 
Similar results were observed in group 2 and 3. Macrophages were identi-
fi  ed as Ham56+ cells (green) and T cells as CD3+ cells (red). n = 5.JEM VOL. 203, April 17, 2006  879
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protein was detected by FACS. All the antibodies were from BD   PharMingen 
except mouse anti–human B7-H4 (clone, hH4.1) (10).
Regulation of B7-H4 expression. Fresh blood monocytes, tumor macro-
phages, and primary ovarian tumor (1–5 × 106/ml) were cultured for diff  er-
ent time with cell-free malignant ascites, or diff  erent concentrations of 
recombinant human IL-10, IL-6, IL-4, and GM-CSF (R & D Systems). 
Neutralizing monoclonal antibody against human IL-6 (anti–IL-6, clone 
6708; 500 ng/ml) and IL-10 (anti–IL-10, clone 23738; 50 ng/ml) (all from 
R & D Systems) and B7-H1 (clone, 5H1; 500–1000 ng/ml) (10) were used 
as indicated. Cells were subject to RT-PCR to detect B7-H4 mRNA and 
to FACS analysis to detect surface or intracellular B7-H4 protein.
Immunofl  uorescence  analysis. Immunofl   uorescence analysis was per-
formed as described (10). Tissues were stained with polyclonal rabbit anti–
human-CD3 (1/10 dilution; Dako), mouse anti–human B7-H4 (hH4.1, 
IgG1; 4 μg/ml) (22), mouse anti–human Ham56 (Ham56, IgM, 1/20; 
Dako) followed by Alexa Fluor 633–conjugated goat anti–rabbit IgG, Alexa 
Fluor 568–conjugated goat anti–mouse IgM, Alexa Fluor 488–conjugated 
goat anti–mouse IgG1, and Alexa Fluor 568–conjugated goat anti–mouse 
IgG2b (all 2 μg/ml; Molecular Probes). Positive cells were quantifi  ed by 
ImagePro Plus software and expressed as the mean of the percentage of posi-
tive cells ± SD in 10 high-powered fi  elds using confocal microscopy.
TAA-specifi  c T cell immunosuppression. MDCs were diff  erentiated 
from monocytes with GM-CSF and IL-4 as described (30). DCs were loaded 
with three distinct HLA-A2–binding Her-2/neu peptides (31) at 5 μg/ml 
each: p369-384 (K I  F  G  S  L  A  F  L  P  E  S  F  D  G  D  P  A  ), p688-703 (R R  L  L  Q  E  T  E  L  V  E-
P  L  T  P  S  ), and p971-984 (E  L  V  S  E  F  S  R  M  A  R  D  P  Q  ), or HLA-A2 infl  uenza   virus 
matrix control peptide GILGFVFTL (Multiple Peptide System). Peptide-
loaded myeloid DCs (TAA-DCs) (1–10 × 103/ml) were used to activate 
autologous tumor CD3+CD25− T cells (105/ml). The tumor macrophage 
to TAA-DC ratio was 0:1, 0.1:1, or 1:1. On day 6, TAA-specifi  c T cell 
  proliferation and cytokines were detected as described (10, 11). T2 cells 
(5 × 106/ml) (American Type Culture Collection) were labeled with 10 μm 
CFSE (Molecular Probes) for 10 min in the dark at 37°C. Cytotoxicity was 
assessed using CFSE-labeled T2 cells bearing all three Her-2/neu peptides 
or matrix control by annexin V staining (26, 56).
Tumor environmental cytokines. The mRNA expressions of IL-6, IL-10, 
IL-4, and GM-CSF were detected by RT-PCR as described (57). IL-6, IL-10, 
IL-4, and GM-CSF proteins were detected by ELISA (R & D Systems).
Polyclonal T cell immunosuppression. Polyclonal T cell immunosup-
pression was tested in a co-culture system. CD3+ T cells (2 × 105/ml) were 
stimulated with 2.5 μg/ml anti–human CD3 (BD Biosciences PharMingen) 
and blood monocytes (2 × 105/ml) in the presence or absence of freshly iso-
lated tumor macrophages or conditioned macrophages as indicated. 72 h after 
co-culture, T cell proliferation, cellular cycle, and cytokine production were 
evaluated as described (10). The selective arginase inhibitor, N-hydroxy-
nor-l-arginine (50 μM) (Calbiochem) and the selective iNOS inhibitor, 
N-monomethyl-l-arginine (1 mM) (Calbiochem) were added into some 
cultures to investigate macrophage-mediated suppressive mechanisms.
B7-H4 blocking experiments. Antisense morpholino oligonucleotide 
specifi  c for B7-H4 (G  A  G  G  A  T  C  T  G  C  C  C  C  A  G  G  G  A  A  G  C  C  A  T  G  ) (B7-H4 
blocking oligo) and the inverted control oligonucleotide (control oligo) 
were produced by GeneTools. To block macrophage B7-H4, monocytes or 
macrophages were incubated for 3 h with 0.6 μM oligo in serum-free me-
dium (X-VIVO 15; Biowittaker) supplemented with 0.2 μM ethoxylated 
polyethylenimine (GeneTools). Cells were washed twice, before use in vitro 
and in vivo assays.
Western blot analysis. Macrophages were resuspended in lysis buff  er 
(50 mM HEPES, 150 mM NaCl, 5 mM EDTA, 1 mM NaOV4, and 0.5% 
Triton X-100) containing 50 μg/ml aprotinin, 50 μg/ml leupeptin, 100 μg/ml 
trypsin-chymotrypsin inhibitor, and 2 mM PMSF. Lysates were centrifuged 
at 3,000 g for 10 min at 4°C. The expression of arginase and iNOS was 
  detected by immunoblot using GAPDH as a housekeeping protein.
B7-H4 transfection. Fresh monocytes or macrophages were transfected 
with 2.5 μg plasmid DNA encoding either human B7-H4 (pcDNA3.1-B7-
H4), the corresponding vector plasmid (pcDNA3.1), or GFP-labeled control 
plasmid as directed (Nucleovector kit; Amaxa Inc.). 20 h after transfection, 
viable cells were subject to in vitro suppression assays.
In vivo tumor regression assay. Primary ovarian tumor cells (107) in 200 μl 
of buff   ered saline were subcutaneously injected into dorsal tissues of 
  fe  male NOD.CB17-SCID mice (6–8 wk old; Jackson  Laboratories) (10). 
Autologous tumor-specifi  c T cells (6 × 106) (10, 26) plus macrophages 
(3 × 106) were injected intravenously into mice on day 12 after human 
  tumor inoculation. Tumor size was measured twice weekly using calipers 
fi  tted with a Vernier scale. Tumor volume was calculated based on three 
perpendicular measurements (10, 26).
Statistical analysis. Diff  erences in cell surface molecule expression were 
determined by χ2 test and in other variables by unpaired Student’s t test, with 
P < 0.05 being considered signifi  cant.
Online supplemental material. Fig. S1 shows the regulation of tumor 
B7-H4 expression. Table S1 displays the phenotype of B7H4+ and B7H4− 
tumor-associated macrophages. Tumor ascites macrophages and tumor cells 
were isolated and sorted as described in Materials and methods. Phenotypes 
of fresh tumor ascites macrophages and B7-H4 in primary and cultured 
  tumor cells were determined by FACS. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20050930/DC1.
We thank Andrew S. Flies for technical assistance.
This work was supported by the Department of Defense (OC020173), National 
Cancer Institute (CA092562, CA100227, CA099985), Louisiana Cancer Research 
Consortium (to W. Zou), and CA97085 (to L. Chen).
The authors have no confl  icting fi  nancial interests.
Submitted: 10 May 2005
Accepted: 15 March 2006
REFERENCES
 1. Spiotto, M.T., P. Yu, D.A. Rowley, M.I. Nishimura, S.C. Meredith, 
T.F. Gajewski, Y.X. Fu, and H. Schreiber. 2002. Increasing tumor anti-
gen expression overcomes “ignorance” to solid tumors via crosspresen-
tation by bone marrow-derived stromal cells. Immunity. 17:737–747.
  2.  Yu, P., Y. Lee, W. Liu, R.K. Chin, J. Wang, Y. Wang, A. Schietinger, 
M. Philip, H. Schreiber, and Y.X. Fu. 2004. Priming of naive T cells 
inside tumors leads to eradication of established tumors. Nat. Immunol. 
5:141–149.
 3. Singh, S., S.R. Ross, M. Acena, D.A. Rowley, and H. Schreiber. 
1992.  Stroma is critical for preventing or permitting immunological 
  destruction of antigenic cancer cells. J. Exp. Med. 175:139–146.
 4. Perdrizet, G.A., S.R. Ross, H.J. Stauss, S. Singh, H. Koeppen, and 
H. Schreiber. 1990.  Animals bearing malignant grafts reject normal 
grafts that express through gene transfer the same antigen. J. Exp. Med. 
171:1205–1220.
 5. Zou, W. 2005. Immunosuppressive networks in the tumour environ-
ment and their therapeutic relevance. Nat. Rev. Cancer. 5:263–274.
 6. Wyckoff  , J., W. Wang, E.Y. Lin, Y. Wang, F. Pixley, E.R. Stanley, 
T. Graf, J.W. Pollard, J. Segall, and J. Condeelis. 2004. A paracrine loop 
between tumor cells and macrophages is required for tumor cell migra-
tion in mammary tumors. Cancer Res. 64:7022–7029.
 7. Pollard, J.W. 2004. Tumour-educated macrophages promote tumour 
progression and metastasis. Nat. Rev. Cancer. 4:71–78.
 8. Vakkila, J., and M.T. Lotze. 2004. Infl  ammation and necrosis promote 
tumour growth. Nat. Rev. Immunol. 4:641–648.880  MACROPHAGE B7-H4 AND TUMOR IMMUNITY | Kryczek et al.
 9. Mantovani, A., S. Sozzani, M. Locati, P. Allavena, and A. Sica. 
2002.  Macrophage polarization: tumor-associated macrophages as a 
paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 
23:549–555.
10. Curiel, T.J., S. Wei, H. Dong, X. Alvarez, P. Cheng, P. Mottram, R. 
Krzysiek, K.L. Knutson, B. Daniel, M.C. Zimmermann, et al. 2003. 
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor 
immunity. Nat. Med. 9:562–567.
11. Zou, W., V. Machelon, A. Coulomb-L’Hermin, J. Borvak, F. Nome, 
T. Isaeva, S. Wei, R. Krzysiek, I. Durand-Gasselin, A. Gordon, et al. 
2001.  Stromal-derived factor-1 in human tumors recruits and   alters 
the function of plasmacytoid precursor dendritic cells. Nat. Med. 
7:1339–1346.
12.  Gabrilovich, D. 2004. Mechanisms and functional signifi  cance of tumour-
induced dendritic-cell defects. Nat. Rev. Immunol. 4:941–952.
13.  Pardoll, D. 2003. Does the immune system see tumors as foreign or self? 
Annu. Rev. Immunol. 21:807–839.
14. Cerundolo, V., I.F. Hermans, and M. Salio. 2004. Dendritic cells: a 
journey from laboratory to clinic. Nat. Immunol. 5:7–10.
15. Gilboa, E. 2004. The promise of cancer vaccines. Nat. Rev. Cancer. 
4:401–411.
16. Munn, D.H., and A.L. Mellor. 2004. IDO and tolerance to tumors. 
Trends Mol. Med. 10:15–18.
17.  Finn, O.J. 2003. Cancer vaccines: between the idea and the reality. Nat. 
Rev. Immunol. 3:630–641.
18. O’Neill, D.W., S. Adams, and N. Bhardwaj. 2004.  Manipulating 
dendritic cell biology for the active immunotherapy of cancer. Blood. 
104:2235–2246.
19. Bingle, L., N.J. Brown, and C.E. Lewis. 2002. The role of tumour-
  associated macrophages in tumour progression: implications for new 
anticancer therapies. J. Pathol. 196:254–265.
20. Zavadova, E., A. Loercher, S. Verstovsek, C.F. Verschraegen, M. 
Micksche, and R.S. Freedman. 1999.  The role of macrophages in 
  antitumor defense of patients with ovarian cancer. Hematol. Oncol. Clin. 
North Am. 13:135–144, ix.
21. Ohno, S., N. Suzuki, Y. Ohno, H. Inagawa, G. Soma, and M. Inoue. 
2003.  Tumor-associated macrophages: foe or accomplice of tumors? 
Anticancer Res. 23:4395–4409.
22.  Sica, G.L., I.H. Choi, G. Zhu, K. Tamada, S.D. Wang, H. Tamura, A.I. 
Chapoval, D.B. Flies, J. Bajorath, and L. Chen. 2003. B7-H4, a mol-
ecule of the B7 family, negatively regulates T cell immunity. Immunity. 
18:849–861.
23.  Prasad, D.V., S. Richards, X.M. Mai, and C. Dong. 2003. B7S1, a novel 
B7 family member that negatively regulates T cell activation. Immunity. 
18:863–873.
24. Zang, X., P. Loke, J. Kim, K. Murphy, R. Waitz, and J.P. Allison. 
2003. B7x: a widely expressed B7 family member that inhibits T cell 
activation. Proc. Natl. Acad. Sci. USA. 100:10388–10392.
25.  Chen, L. 2004. Co-inhibitory molecules of the B7-CD28 family in the 
control of T-cell immunity. Nat. Rev. Immunol. 4:336–347.
26. Curiel, T.J., G. Coukos, L. Zou, X. Alvarez, P. Cheng, P. Mottram, 
M. Evdemon-Hogan, J.R. Conejo-Garcia, L. Zhang, M. Burow, et al. 
2004. Specifi  c recruitment of regulatory T cells in ovarian carcinoma 
fosters immune privilege and predicts reduced survival. Nat. Med. 
10:942–949.
27. Zou, W. 2006. Regulatory T cells, tumour immunity. and immuno-
therapy. Nat. Rev. Immunol. 6:295–307. 
28. Kryczek, I., S. Wei, L. Zou, G. Zhu, P. Mottram, L. Chen, and W. 
Zou. Induction of B7-H4 on antigen presenting cells through inter-
leukin 10: novel suppressive mode for regulatory T cells. J. Immunol. 
In press.
29. Kryczek, I., A. Lange, P. Mottram, X. Alvarez, P. Cheng, M. Hogan, 
L. Moons, S. Wei, L. Zou, V. Machelon, et al. 2005. CXCL12 and vas-
cular endothelial growth factor synergistically induce neoangiogenesis 
in human ovarian cancers. Cancer Res. 65:465–472.
30. Zou, W., J. Borvak, F. Marches, S. Wei, P. Galanaud, D. Emilie, and 
T.J. Curiel. 2000. Macrophage-derived dendritic cells have strong Th1-
polarizing potential mediated by beta-chemokines rather than IL-12.
J. Immunol. 165:4388–4396.
31. Knutson, K.L., K. Schiff   man, and M.L. Disis. 2001.  Immunization 
with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 
T-cell immunity in cancer patients. J. Clin. Invest. 107:477–484.
32.  Rodriguez, P.C., A.H. Zea, J. DeSalvo, K.S. Culotta, J. Zabaleta, D.G. 
Quiceno, J.B. Ochoa, and A.C. Ochoa. 2003. L-arginine consumption 
by macrophages modulates the expression of CD3 zeta chain in T lym-
phocytes. J. Immunol. 171:1232–1239.
33.  Rodriguez, P.C., D.G. Quiceno, J. Zabaleta, B. Ortiz, A.H. Zea, M.B. 
Piazuelo, A. Delgado, P. Correa, J. Brayer, E.M. Sotomayor, et al. 
2004. Arginase I production in the tumor microenvironment by mature 
myeloid cells inhibits T-cell receptor expression and antigen-specifi  c 
T-cell responses. Cancer Res. 64:5839–5849.
34.  Sinha, P., V.K. Clements, and S. Ostrand-Rosenberg. 2005. Reduction 
of myeloid-derived suppressor cells and induction of M1 macrophages 
facilitate the rejection of established metastatic disease. J. Immunol. 
174:636–645.
35.  Kusmartsev, S., Y. Nefedova, D. Yoder, and D.I. Gabrilovich. 
2004. Antigen-specifi  c inhibition of CD8+ T cell response by imma-
ture myeloid cells in cancer is mediated by reactive oxygen species. 
J. Immunol. 172:989–999.
36. Rodriguez, P.C., C.P. Hernandez, D. Quiceno, S.M. Dubinett, J. 
Zabaleta, J.B. Ochoa, J. Gilbert, and A.C. Ochoa. 2005. Arginase I in 
myeloid suppressor cells is induced by COX-2 in lung carcinoma. 
J. Exp. Med. 202:931–939.
37. Bronte, V., P. Serafi  ni, E. Apolloni, and P. Zanovello. 2001. Tumor-
induced immune dysfunctions caused by myeloid suppressor cells. 
J. Immunother. 24:431–446.
38.  Bronte, V., P. Serafi  ni, C. De Santo, I. Marigo, V. Tosello, A. Mazzoni, 
D.M. Segal, C. Staib, M. Lowel, G. Sutter, et al. 2003. IL-4-induced 
arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol.
170:270–278.
39. Bronte, V., and P. Zanovello. 2005. Regulation of immune responses 
by L-arginine metabolism. Nat. Rev. Immunol. 5:641–654.
40. Bronte, V., T. Kasic, G. Gri, K. Gallana, G. Borsellino, I. Marigo, 
L. Battistini, M. Iafrate, T. Prayer-Galetti, F. Pagano, and A. Viola. 
2005.  Boosting antitumor responses of T lymphocytes infi  ltrating 
human prostate cancers. J. Exp. Med. 201:1257–1268.
41. Mazzoni, A., V. Bronte, A. Visintin, J.H. Spitzer, E. Apolloni, P. 
Serafi  ni, P. Zanovello, and D.M. Segal. 2002. Myeloid suppressor lines 
inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 
168:689–695.
42. Dong, H., S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, D.B. 
Flies, P.C. Roche, J. Lu, G. Zhu, K. Tamada, et al. 2002. Tumor-
associated B7-H1 promotes T-cell apoptosis: A potential mechanism of 
immune evasion. Nat. Med. 8:793–800.
43.  Strome, S.E., H. Dong, H. Tamura, S.G. Voss, D.B. Flies, K. Tamada, 
D. Salomao, J. Cheville, F. Hirano, W. Lin, et al. 2003. B7-H1 block-
ade augments adoptive T-cell immunotherapy for squamous cell carci-
noma. Cancer Res. 63:6501–6505.
44. Shevach, E.M. 2002.  CD4+ CD25+ suppressor T cells: more ques-
tions than answers. Nat. Rev. Immunol. 2:389–400.
45. Sakaguchi, S., N. Sakaguchi, J. Shimizu, S. Yamazaki, T. Sakihama, 
M. Itoh, Y. Kuniyasu, T. Nomura, M. Toda, and T. Takahashi. 
2001. Immunologic tolerance maintained by CD25+ CD4+ regula-
tory T cells: their common role in controlling autoimmunity, tumor 
immunity, and transplantation tolerance. Immunol. Rev. 182:18–32.
46.  Von Herrath, M.G., and L.C. Harrison. 2003. Regulatory lymphocytes: 
antigen-induced regulatory T cells in autoimmunity. Nat. Rev. Immunol. 
3:223–232.
47.  Woo, E.Y., H. Yeh, C.S. Chu, K. Schlienger, R.G. Carroll, J.L. Riley, 
L.R. Kaiser, and C.H. June. 2002. Regulatory T cells from lung can-
cer patients directly inhibit autologous T cell proliferation. J. Immunol. 
168:4272–4276.
48. Mills, C.D., K. Kincaid, J.M. Alt, M.J. Heilman, and A.M. Hill. 
2000. M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 
164:6166–6173.
49. Kusmartsev, S.A., Y. Li, and S.H. Chen. 2000. Gr-1+ myeloid cells 
derived from tumor-bearing mice inhibit primary T cell activation 
  induced through CD3/CD28 costimulation. J. Immunol. 165:779–785.JEM VOL. 203, April 17, 2006  881
ARTICLE
50.  Hellstrom, K.E., and I. Hellstrom. 2003. Novel approaches to therapeu-
tic cancer vaccines. Expert Rev. Vaccines. 2:517–532.
51.  Khong, H.T., and N.P. Restifo. 2002. Natural selection of tumor vari-
ants in the generation of “tumor escape” phenotypes. Nat. Immunol. 
3:999–1005.
52. Schreiber, H., T.H. Wu, J. Nachman, and W.M. Kast. 2002. Immuno-
dominance and tumor escape. Semin. Cancer Biol. 12:25–31.
53.  Abbud, R.A., C.K. Finegan, L.A. Guay, and E.A. Rich. 1995. Enhanced 
production of human immunodefi  ciency virus type 1 by in vitro-  infected 
alveolar macrophages from otherwise healthy cigarette   smokers. J. Infect. 
Dis. 172:859–863.
54.  van Elsas, A., R.P. Sutmuller, A.A. Hurwitz, J. Ziskin, J. Villasenor, J.P. 
Medema, W.W. Overwijk, N.P. Restifo, C.J. Melief, R. Off  ringa, and 
J.P. Allison. 2001. Elucidating the autoimmune and antitumor eff  ector 
mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 
blockade in combination with a B16 melanoma vaccine: comparison of 
prophylaxis and therapy. J. Exp. Med. 194:481–489.
55. Levitsky, H.I., A. Lazenby, R.J. Hayashi, and D.M. Pardoll. 1994. In 
vivo priming of two distinct antitumor eff  ector populations: the role of 
MHC class I expression. J. Exp. Med. 179:1215–1224.
56. Lecoeur, H., M. Fevrier, S. Garcia, Y. Riviere, and M.L. Gougeon. 
2001. A novel fl  ow cytometric assay for quantitation and multiparamet-
ric characterization of cell-mediated cytotoxicity. J. Immunol. Methods. 
253:177–187.
57.  Zou, W., I. Durand-Gasselin, A. Dulioust, M.C. Maillot, P. Galanaud, 
and D. Emilie. 1995. Quantifi  cation of cytokine gene expression by 
competitive PCR using a colorimetric assay. Eur. Cytokine Netw. 
6:257–264.